Inspira Technologies Oxy B.H.N. Ltd. logo

Inspira Technologies Oxy B.H.N. Ltd. (IINN)

Market Closed
17 Dec, 20:00
NASDAQ (CM) NASDAQ (CM)
$
1. 00
-0.02
-2.07%
$
24.57M Market Cap
- P/E Ratio
0% Div Yield
104,833 Volume
0 Eps
$ 1.02
Previous Close
Day Range
0.99 1.06
Year Range
0.4 1.65
Want to track IINN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 83 days

Summary

IINN closed today lower at $1, a decrease of 2.07% from yesterday's close, completing a monthly decrease of -13.14% or $0.15. Over the past 12 months, IINN stock lost -4.87%.
IINN is not paying dividends to its shareholders.
The last earnings report, released on Nov 19, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.1%, based on the last three reports. The next scheduled earnings report is due on Mar 11, 2026.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

IINN Chart

Similar

Cytosorbents Corporation
$ 0.64
+0.47%
Kalaris Therapeutics, Inc.
$ 9.81
+4.14%
CUE
Cue Biopharma Inc.
$ 0.4
-2.44%
Spectral AI Inc.
$ 1.42
-5.33%
IceCure Medical Ltd.
$ 0.68
+8.68%
Inspira Stock to Gain From its Appearance at Annual ELSO Conference

Inspira Stock to Gain From its Appearance at Annual ELSO Conference

At the 34th annual ELSO conference in Detroit, IINN will present its FDA-cleared latest and future technology, the INSPIRA ART100 system.

Zacks | 1 year ago
IINN Stock Gains on Second US Patent Approval for VORTX System

IINN Stock Gains on Second US Patent Approval for VORTX System

Inspira secures a second U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system.

Zacks | 1 year ago
Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock

Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock

IINN plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients in the fourth quarter of 2024.

Zacks | 1 year ago

Inspira Technologies Oxy B.H.N. Ltd. (IINN) FAQ

What is the stock price today?

The current price is $1.00.

On which exchange is it traded?

Inspira Technologies Oxy B.H.N. Ltd. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is IINN.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 24.57M.

When is the next earnings date?

The next earnings report will release on Mar 11, 2026.

Has Inspira Technologies Oxy B.H.N. Ltd. ever had a stock split?

No, there has never been a stock split.

Inspira Technologies Oxy B.H.N. Ltd. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Dagi Shahar Ben-Noon CEO
NASDAQ (CM) Exchange
M53637100 CUSIP
IL Country
37 Employees
- Last Dividend
- Last Split
14 Jul 2021 IPO Date

Overview

Inspira Technologies Oxy B.H.N. Ltd., headquartered in Ra'annana, Israel, stands at the forefront of specialty medical device innovation, concentrating on the development and dissemination of advanced respiratory support technologies. Founded in 2018, the company was initially known as Insense Medical Ltd. before rebranding in July 2020 to its current title. Inspira Technologies is dedicated to offering groundbreaking solutions aimed at transforming the treatment landscape for patients suffering from acute respiratory failure. By focusing on the development, manufacture, and marketing of its proprietary systems, Inspira Technologies aims to furnish healthcare providers with viable alternatives to traditional invasive mechanical ventilation methods, marking a significant step forward in patient care and treatment efficacy.

Products and Services

Augmented Respiration Technology System: At the heart of Inspira Technologies’ offerings is its flagship product, the augmented respiration technology (ART) system. This innovative respiratory support system encompasses a minimally invasive, portable dual lumen cannula that is carefully inserted into the jugular vein of patients. The ART system stands out by employing extra-corporeal direct blood oxygenation technology. By directly oxygenating the blood outside the body, the system effectively elevates and stabilizes oxygen saturation levels in patients experiencing acute respiratory failures. This groundbreaking approach not only aims to improve patient outcomes but also seeks to reduce the need for, and the associated risks of, traditional invasive mechanical ventilation. Inspira Technologies’ commitment to fostering advancements in non-invasive respiratory support shines through this cutting-edge product, promising a new era of medical care for patients grappling with severe respiratory conditions.

Contact Information

Address: Ha-Tidhar St 2
Phone: 972 4 623 0333